Frontline Endocrine Therapies And Ribociclib In Early Stage Hr+ Her2- Breast Cancer

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patients

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy

Ribociclib in Early Breast Cancer | NEJM

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast Cancer

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

European Society for Medical Oncology (ESMO)

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer

NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer

monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancer

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

Ribociclib in adjuvant HR+ breast cancer

OncBrothers: Practice-Changing Cancer Discussions

MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC

Unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer

Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer

MDedge: news and insights for busy physicians

What is the role of CDK4/6 inhibitors in early breast cancer?

Inclusion criteria for NATALEE Trial - evaluating importance of ajuvant ribociclib #oncology #cancer

OncBrothers: Practice-Changing Cancer Discussions

Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer

RIGHT Choice: ribociclib + ET vs combo chemo in aggressive HR+/HER2− advanced breast cancer